• According to Transparency Market Research’s latest report on the global geriatric medicine market for the historical period 2017–2018 and forecast period 2019–2027, rise in chronic diseases, increase in governments and NGOs supports for elderly and technological advancement for medication assistance are projected to drive the global geriatric medicine market during the forecast period
  • According to the report, the global geriatric medicine market was valued at US$ 672.0 Bn in 2018 and is anticipated to expand at a CAGR of 6.9% from 2019 to 2027
fa global geriatric medicine market

To know the scope of our report Get a Sample on Geriatric Medicines Market?

Increase in global geriatric population and Surge in Programs by Governments and NGOs to support Elderly Patients: Key Drivers

  • Rise in geriatric population has led to an increase in the incidence and prevalence of chronic diseases. According to the World Health Organization (WHO), people over the age of 65 form the fastest-growing population segment globally. The proportion of the world's population over 60 years is expected to double from about 11% to 22% between 2000 and 2050.
  • Stroke is a leading cause of death in the U.S. According to the Centers for Disease Control and Prevention (CDC), stroke claims one fatality every 40 seconds in the U.S. and about 795,000 people become victims of stroke (85% acute ischemic) each year. About 610,000 of these are first or new strokes, and 185,000 are recurrent strokes.
  • The global geriatric medicines market is expanding at a significant growth rate due to increasing government support toward old people for their health, safety, and nursing care. The Federal Long Term Care Insurance Program in the U.S. is a favorable policy for the elderly people, which covers almost all the medical care/cost of people in the U.S. Likewise, the Long-Term Care Ombudsman Program provides nursing homes, residential care facilities, and assisted living facilities for elderly people in the U.S.

Get a glimpse of the in-depth analysis through our Report Brochure

Technological Advancement for Medication Assistance Boost Market Growth

  • The elderly are presently able to manage their multiple prescription drugs problem owing to recent advances in technology. There are pill boxes with alarms that enable seniors to know what exact pill needs to be taken and when. Several companies are developing and selling smart pill bottles.
  • These pill bottles allow connecting their medications to doctors and pharmacies for data on how often patients are taking their medication. They also alert (like a text message or phone call) the elderly about the appropriate time to take their medication, in case they forget. Therefore, technological advancement in medical assistance is likely to drive geriatric medicine market globally

Side Effects in Elderly to Hamper Market

  • Elderly people are more sensitive to frequently used drugs such as benzodiazepines, NSAIDs, and opioids. High chances of adverse drug reaction (ADR) and overdose in the elderly can lead to uptake of other form of therapies (herbal medicines, Unani, physiotherapy etc.), which in turn is projected to hamper the geriatric medicines market

Global Geriatric medicine Market: Competitive Landscape

  • This report profiles major players in the global geriatric medicine market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global geriatric medicine market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global geriatric medicine market are
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Sanofi S.A.
    • GlaxoSmithKline plc Eli Lilly and Company
    • Abbott Laboratories
    • Boehringer Ingelheim GmbH 

Expanding operations in future? To get the perfect launch ask for a custom report 

Global Geriatric medicine Market: Key Developments

Key players in the global geriatric medicine market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global geriatric medicine market. A few expansion strategies adopted by players operating in the global geriatric medicine market are:

  • In October 2018, The U.S. Food and Drug Administration approved Dupixent (dupilumab) as an add-on maintenance therapy in patients aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma
  • In June 2017, Eli Lilly and Company received approval from the U.S. FDA for Humalog Junior KwikPen. The prefilled Humalog Junior KwikPen can help make insulin injections easier to incorporate into everyday lives.
  • In April 2016, Astellas Pharma Inc. and Amgen Inc. announced the launch of Repatha in Japan. Repatha is a PCSK9 inhibitor to treat patients with familial hypercholesterolemia having a high risk of cardiovascular diseases.

The report on the global geriatric medicine market discussed individual strategies, followed by company profiles of manufacturers of geriatric medicine. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global geriatric medicine market.

TMR’s report on the global geriatric medicine market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2019 to 2027. The report provides revenue of the global geriatric medicine market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global geriatric medicine market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global geriatric medicine market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global geriatric medicine market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global geriatric medicine market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global geriatric medicine market.

The report delves into the competitive landscape of the global geriatric medicine market. Key players operating in the global geriatric medicine market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global geriatric medicine market that have been profiled in this report.

Key Questions Answered in Global Geriatric Medicine Market Report

  • What is the scope of growth of product companies in the global geriatric medicine market?
  • What will be the Y-o-Y growth of the global geriatric medicine market between 2019 and 2027?
  • What is the influence of changing trends in the global geriatric medicine market?
  • Will North America continue to be the most profitable market for geriatric medicine providers?
  • Which factors are anticipated to hamper the growth of the global geriatric medicine market during the forecast period?
  • Which are the leading companies in the global geriatric medicine market?

Research Methodology

A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global geriatric medicine market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global geriatric medicine market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the geriatric medicine market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the geriatric medicine market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global geriatric medicine market with accuracy. The study also uses the top-down approach to assess the revenues for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global geriatric medicine market more reliably and accurately.

Regional Segmentation of Geriatric Medicine Market

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Global Geriatric Medicine Market – Segmentation

Therapeutic Category

Analgesic

Antihypertensive

Statins

Antidiabetic

Proton Pump Inhibitor

Anticoagulant

Antipsychotic and Antidepressant

Others

Condition

Cardiovascular

Arthritis

Diabetes

Neurological

Cancer

Osteoporosis

Respiratory

Others

Distribution Channels

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Geriatric Medicine Market

4. Market Overview

    4.1. Introduction

        4.1.1.  Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Geriatric Medicine Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Regulatory Scenario, by Region/Globally

    5.2. Pipeline Analysis

    5.3. Mergers & Acquisitions 

6. Global Geriatric Medicine Market Analysis and Forecast, by Therapeutic Category

    6.1. Introduction & Definition

        6.1.1. Key Findings / Developments

    6.2. Global Geriatric Medicine Market Value Forecast, by Therapeutic Category, 2017–2027

        6.2.1. Analgesic

        6.2.2. Antihypertensive

        6.2.3. Statins

        6.2.4. Antidiabetic

        6.2.5. Proton Pump Inhibitor

        6.2.6. Anticoagulant

        6.2.7. Antipsychotic and Antidepressant

        6.2.8. Others

    6.3. Global Geriatric Medicine Market Attractiveness, by Therapeutic Category

7. Global Geriatric Medicine Market Analysis and Forecast, by Condition

    7.1. Introduction & Definition

        7.1.1. Key Findings / Developments

    7.2. Global Geriatric Medicine Market Value Forecast, by Condition, 2017–2027

        7.2.1. Cardiovascular

        7.2.2. Arthritis

        7.2.3. Diabetes

        7.2.4. Neurological

        7.2.5. Cancer

        7.2.6. Osteoporosis

        7.2.7. Respiratory

        7.2.8. Others

    7.3. Global Geriatric Medicine Market Attractiveness, by Condition

8. Global Geriatric Medicine Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

        8.1.1. Key Findings / Developments

    8.2. Global Geriatric Medicine Market Value Forecast, by Distribution Channel, 2017–2027

        8.2.1. Hospital Pharmacies

        8.2.2. Retail Pharmacies

        8.2.3. Online Pharmacies

    8.3. Global Geriatric Medicine Market Attractiveness, by Distribution Channel

9. Global Geriatric Medicine Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Global Geriatric Medicine Market Value Forecast, by Region

        9.2.1. North America 

        9.2.2. Europe 

        9.2.3. Asia Pacific 

        9.2.4. Latin America 

        9.2.5. Middle East & Africa 

    9.3. Global Geriatric Medicine Market Attractiveness, by Region

10. North America Geriatric Medicine Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. North America Geriatric Medicine Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

        10.2.1. Analgesic

        10.2.2. Antihypertensive

        10.2.3. Statins

        10.2.4. Antidiabetic

        10.2.5. Proton Pump Inhibitor

        10.2.6. Anticoagulant

        10.2.7. Antipsychotic and Antidepressant

        10.2.8. Others

    10.3. North America Geriatric Medicine Market Value (US$ Mn) Forecast, by Condition, 2017–2027

        10.3.1. Cardiovascular

        10.3.2. Arthritis

        10.3.3. Diabetes

        10.3.4. Neurological

        10.3.5. Cancer

        10.3.6. Osteoporosis

        10.3.7. Respiratory

        10.3.8. Others

    10.4. North America Geriatric Medicine Market Value (US$ Mn) Forecast, by Distribution Channels, 2017–2027

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. North America Geriatric Medicine Market Value (US$ Mn) Forecast, by Country, 2017–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Geriatric Medicine Market Attractiveness Analysis 

        10.6.1. By Therapeutic Category

        10.6.2. By Condition

        10.6.3. By Distribution Channels

        10.6.4. By Country

11. Europe Geriatric Medicine Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Europe Geriatric Medicine Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

        11.2.1. Analgesic

        11.2.2. Antihypertensive

        11.2.3. Statins

        11.2.4. Antidiabetic

        11.2.5. Proton Pump Inhibitor

        11.2.6. Anticoagulant

        11.2.7. Antipsychotic and Antidepressant

        11.2.8. Others

    11.3. Europe Geriatric Medicine Market Value (US$ Mn) Forecast, by Condition, 2017–2027

        11.3.1. Cardiovascular

        11.3.2. Arthritis

        11.3.3. Diabetes

        11.3.4. Neurological

        11.3.5. Cancer

        11.3.6. Osteoporosis

        11.3.7. Respiratory

        11.3.8. Others

    11.4. Europe Geriatric Medicine Market Value (US$ Mn) Forecast, by Distribution Channels, 2017–2027

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Europe Geriatric Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe 

    11.6. Europe Geriatric Medicine Market Attractiveness Analysis 

        11.6.1. By Therapeutic Category

        11.6.2. By Condition

        11.6.3. By Distribution Channels

        11.6.4. By Country/Sub-region

12. Asia Pacific Geriatric Medicine Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Asia Pacific Geriatric Medicine Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

        12.2.1. Analgesic

        12.2.2. Antihypertensive

        12.2.3. Statins

        12.2.4. Antidiabetic

        12.2.5. Proton Pump Inhibitor

        12.2.6. Anticoagulant

        12.2.7. Antipsychotic and Antidepressant

        12.2.8. Others

    12.3. Asia Pacific Geriatric Medicine Market Value (US$ Mn) Forecast, by Condition, 2017–2027

        12.3.1. Cardiovascular

        12.3.2. Arthritis

        12.3.3. Diabetes

        12.3.4. Neurological

        12.3.5. Cancer

        12.3.6. Osteoporosis

        12.3.7. Respiratory

        12.3.8. Others

    12.4. Asia Pacific Geriatric Medicine Market Value (US$ Mn) Forecast, by Distribution Channels, 2017–2027

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Asia Pacific Geriatric Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific 

    12.6. Asia Pacific Geriatric Medicine Market Attractiveness Analysis 

        12.6.1. By Therapeutic Category

        12.6.2. By Condition

        12.6.3. By Distribution Channels

        12.6.4. By Country/Sub-region

13. Latin America Geriatric Medicine Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Latin America Geriatric Medicine Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

        13.2.1. Analgesic

        13.2.2. Antihypertensive

        13.2.3. Statins

        13.2.4. Antidiabetic

        13.2.5. Proton Pump Inhibitor

        13.2.6. Anticoagulant

        13.2.7. Antipsychotic and Antidepressant

        13.2.8. Others

    13.3. Latin America Geriatric Medicine Market Value (US$ Mn) Forecast, by Condition, 2017–2027

        13.3.1. Cardiovascular

        13.3.2. Arthritis

        13.3.3. Diabetes

        13.3.4. Neurological

        13.3.5. Cancer

        13.3.6. Osteoporosis

        13.3.7. Respiratory

        13.3.8. Others

    13.4. Latin America Geriatric Medicine Market Value (US$ Mn) Forecast, by Distribution Channels, 2017–2027

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Latin America Geriatric Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America Latin America 

    13.6. Latin America Geriatric Medicine Market Attractiveness Analysis 

        13.6.1. By Therapeutic Category

        13.6.2. By Condition

        13.6.3. By Distribution Channels

        13.6.4. By Country/Sub-region

14. Middle East & Africa Geriatric Medicine Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Middle East & Africa Geriatric Medicine Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

        14.2.1. Analgesic

        14.2.2. Antihypertensive

        14.2.3. Statins

        14.2.4. Antidiabetic

        14.2.5. Proton Pump Inhibitor

        14.2.6. Anticoagulant

        14.2.7. Antipsychotic and Antidepressant

        14.2.8. Others

    14.3. Middle East & Africa Geriatric Medicine Market Value (US$ Mn) Forecast, by Condition, 2017–2027

        14.3.1. Cardiovascular

        14.3.2. Arthritis

        14.3.3. Diabetes

        14.3.4. Neurological

        14.3.5. Cancer

        14.3.6. Osteoporosis

        14.3.7. Respiratory

        14.3.8. Others

    14.4. Middle East & Africa Geriatric Medicine Market Value (US$ Mn) Forecast, by Distribution Channels, 2017–2027

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Middle East & Africa Geriatric Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa 

    14.6. Middle East & Africa Geriatric Medicine Market Attractiveness Analysis 

        14.6.1. By Therapeutic Category

        14.6.2. By Condition

        14.6.3. By Distribution Channels

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by Tier and Size of companies)

    15.2. Company Profiles

        15.2.1. Pfizer, Inc.

            15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.1.2. Growth Strategies

            15.2.1.3. SWOT Analysis

        15.2.2. Merck & Co., Inc. 

            15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.2.2. Growth Strategies

            15.2.2.3. SWOT Analysis

        15.2.3. AstraZeneca 

            15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.3.2. Growth Strategies

            15.2.3.3. SWOT Analysis

        15.2.4. Bristol-Myers Squibb Company 

            15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.4.2. Growth Strategies

            15.2.4.3. SWOT Analysis

        15.2.5. Novartis AG

            15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.5.2. Growth Strategies

            15.2.5.3. SWOT Analysis

        15.2.6. Sanofi S.A. 

            15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.6.2. Growth Strategies

            15.2.6.3. SWOT Analysis 

        15.2.7. GlaxoSmithKline plc 

            15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.7.2. Growth Strategies

            15.2.7.3. SWOT Analysis

        15.2.8. Eli Lilly and Company 

            15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.8.2. Growth Strategies

            15.2.8.3. SWOT Analysis

        15.2.9. Abbott Laboratories 

            15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.9.2. Growth Strategies

            15.2.9.3. SWOT Analysis

        15.2.10. Boehringer Ingelheim GmbH

            15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.10.2. Growth Strategies

            15.2.10.3. SWOT Analysis

List of Table

Table 01: Major Causes of Death for Persons Aged 65 or Over, 2014 (Standardized Death Rates per 100,000 Inhabitants)

Table 02: Healthcare Overview (2016 or latest available)

Table 03: Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2017

Table 04: Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2017–2017

Table 05: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2017

Table 06: Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Region, 2017–2017

Table 07: North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

Table 08: North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2017–2027

Table 09: North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2017

Table 10: North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Country, 2017–2017

Table 11: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

Table 12: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2017–2027

Table 13: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2017

Table 14: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2017

Table 15: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

Table 16: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2017–2027

Table 17: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2017

Table 18: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2017

Table 19: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

Table 20: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2017–2027

Table 21: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2017

Table 22: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2017

Table 23: Middle East & Africa (MEA) Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

Table 24: Middle East & Africa (MEA) Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2017–2027

Table 25: Middle East & Africa (MEA) Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2017

Table 26: Middle East & Africa (MEA) Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2017

List of Figure

Figure 01: Global Geriatric Medicines Market Snapshot

Figure 02: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2027

Figure 04: Market Value Share By Condition (2018)

Figure 06: Market Value Share By Region (2018)

Figure 03: Market Value Share By Therapeutic Category (2018)

Figure 05: Market Value Share By Distribution Channel (2018)

Figure 07: Global Geriatric Medicines Market Value Share, by Therapeutic Category, 2018 and 2027

Figure 08: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Analgesics

Figure 09: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Antihypertensive

Figure 10: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Statins

Figure 11: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Antidiabetic

Figure 12: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Proton Pump Inhibitor

Figure 13: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Anticoagulant 

Figure 14: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Antipsychotic and Antidepressant 

Figure 15: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Others 

Figure 16: Global Geriatric Medicines Market Value Share, by Condition, 2018 and 2027

Figure 17: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Cardiovascular

Figure 18: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Arthritis

Figure 19: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Diabetes

Figure 20: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Neurological 

Figure 21: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Cancer

Figure 22: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Osteoporosis 

Figure 23: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Antipsychotic and Antidepressant 

Figure 24: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Others 

Figure 25: Global Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 26: Global Geriatric Medicines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027

Figure 27: Global Geriatric Medicines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027

Figure 28: Global Geriatric Medicines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027

Figure 29: Global Geriatric Medicines Market Value Share, by Region, 2018 and 2027

Figure 30: North America Geriatric Medicines Market Value (US$ Mn) Forecast, 2017–2027

Figure 31: North America Market Attractiveness Analysis, by Country

Figure 32: North America Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2018 and 2027

Figure 33: North America Geriatric Medicines Market Value Share Analysis, by Condition, 2018 and 2027

Figure 34: North America Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 35: North America Geriatric Medicines Market Value Share Analysis, by Country, 2018 and 2027

Figure 36: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, 2017–2027

Figure 37: Europe Market Attractiveness Analysis, by Country/Sub-region

Figure 38: Europe Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2018 and 2027

Figure 39: Europe Geriatric Medicines Market Value Share Analysis, by Condition, 2018 and 2027

Figure 40: Europe Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 41: Europe Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 42: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, 2017–2027

Figure 43: Asia Pacific Market Attractiveness Analysis, by Country

Figure 44: Asia Pacific Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2018 and 2027

Figure 45: Asia Pacific Geriatric Medicines Market Value Share Analysis, by Condition, 2018 and 2027

Figure 46: Asia Pacific Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 47: Asia Pacific Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 48: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, 2017–2027

Figure 49: Latin America Market Attractiveness Analysis, by Country

Figure 50: Latin America Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2018 and 2027

Figure 51: Latin America Geriatric Medicines Market Value Share Analysis, by Condition, 2018 and 2027

Figure 52: Latin America Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 53: Latin America Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 54: Middle East & Africa (MEA) Geriatric Medicines Market Value (US$ Mn) Forecast, 2017–2027

Figure 55: Middle East & Africa (MEA) Market Attractiveness Analysis, by Country/Sub-region

Figure 56: Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2018 and 2027

Figure 57: Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Condition, 2018 and 2027

Figure 58: Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 59: Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 60: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

Figure 61: Pfizer, Inc. R&D Intensity (%) - Company Level or Segment Level, 2016–2018

Figure 62: Pfizer, Inc. Breakdown of Net Sales, by Region, 2017

Figure 63: Merck & Co., Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

Figure 64: Merck & Co., Inc. R&D Intensity (%) - Company Level or Segment Level, 2016–2018

Figure 65: Merck & Co., Inc. Break-up of Net Sales, by Region, 2017

Figure 66: AstraZeneca Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

Figure 67: AstraZeneca Breakdown of Net Sales, by Region, 2018

Figure 68: AstraZeneca Marketing & Sales and R&D Expenses, 2016–2018

Figure 69: Bristol-Myers Squibb Company Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

Figure 70: Bristol-Myers Squibb Company R&D Intensity (%) - Company Level or Segment Level, 2016–2018

Figure 71: Bristol-Myers Squibb Company Breakdown of Net Sales, by Region, 2018

Figure 72: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

Figure 73: Novartis AG Marketing & Sales and R&D Expenses, 2016–2018

Figure 74: Novartis AG Breakdown of Net Sales, by Business Segment, 2018

Figure 75: Novartis AG Breakdown of Net Sales, by Region, 2018

Figure 76: Sanofi S.A. Breakdown of Net Sales, by Region, 2018

Figure 77: Sanofi S.A. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

Figure 78: Sanofi S.A. Breakdown of Net Sales, by Business Segment, 2018

Figure 79: Sanofi S.A. R&D Intensity and Sales & Marketing Intensity (Pharmaceutical Segment) - Company Level, 2016–2018

Figure 80: GlaxoSmithKline plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

Figure 81: GlaxoSmithKline plc Marketing & Sales and R&D Expenses, 2016–2018

Figure 82: GlaxoSmithKline plc Breakdown of Net Sales, by Business Segment, 2018

Figure 83: GlaxoSmithKline plc Breakdown of Net Sales, by Region, 2018

Figure 84: Eli Lilly and Company Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 85: Eli Lilly and Company R&D Intensity (%) - Company Level or Segment Level, 2016–2018

Figure 86: Eli Lilly and Company Breakdown of Net Sales, by Region, 2018

Figure 87: Abbott Laboratories, Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 88: Abbott Laboratories, Breakdown of Net Sales, by Business Segment, 2018

Figure 89: Abbott Laboratories, Breakdown of Net Sales, by Region 2018

Figure 90: Boehringer Ingelheim GmbH, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 91: Boehringer Ingelheim GmbH, Breakdown of Net Sales, by Business Segment, 2018

Figure 92: Boehringer Ingelheim GmbH, Breakdown of Net Sales, by Region 2018

Figure 93: Boehringer Ingelheim GmbH, R&D (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Geriatric Medicine Market